CHMP recommends expanded label for AbbVie’s Kaletra to treat HIV infection in infants

EMA’s CHMP recommended expanding the label for Kaletra lopinavir/ritonavir from AbbVie Inc. (NYSE:ABBV) to treat HIV-1 infection in children aged ≥14 days. Kaletra is currently approved in the EU to treat HIV-1 infection in patients aged >2 years...